Testing a new treatment for people with Crohn's Disease
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy of different doses of SAR441566 compared with placebo in participants with moderate to severe CD.
What you need to know
Who can take part?
To be eligible to take part you must:
Be aged 18 to 75
Have a confirmed diagnosis of CD for at least 3 months
Have confirmed diagnosis of moderate to severe CD
Not be pregnant or planning pregnancy
Not have any other bowel condition
Not have an active infection
Not have a recent history of malignancy
Meet the study requirements regarding current & prior treatments
What is involved for me?
Regular study clinic visits
Daily eDiary completion
Oral therapy (tablets)
Colonoscopy
Blood tests
Urine tests
Stool tests
ECG
Questionnaires at study visits
